AUS
NZ
UK
CA
USA
IND
Healt
Is (ASX:ANN) Misread by Markets in the ASX 200 Value Debate?
December 04, 2025 02:47 PM AEDT| By SamAnsell’s valuation debate shows how markets weigh risk against cash-flow durability. The most important drivers are discount rate assumptions, long-run growth views, and confidence in steady cash conversion.
Pro Medicus (ASX:PME) Faces Data Breach: What Investors Should Know
December 04, 2025 12:36 PM AEDT| By SamPro Medicus (ASX:PME) confirmed an isolated data breach affecting a single email inbox at its subsidiary Visage Imaging. No client systems, patient data, or financial operations were impacted.
ECS Botanics Sets Stage for AVANI AVA Women’s-Health Cannabis Launch in 2026
December 04, 2025 12:16 PM AEDT| By SamECS Botanics (ASX:ECS) is preparing to introduce AVANI AVA, a women-centered medicinal cannabis range arriving in early twenty-six. This detailed article explores the strategic expansion, product design, industry relevance
ASX 300 Sees Quiet Aged-Care Move Drawing New Interest
December 04, 2025 11:05 AM AEDT| By SamA deep dive into the latest aged-care portfolio shift involving Regis Healthcare (ASX:REG), exploring how a major divestment aligns with sector trends across the broader ASX stock market and the evolving landscape of Australian healthcare services.
Philips Partnership Boosts 4DMedical’s Global Expansion
December 03, 2025 03:02 PM AEDT| By Team Kalkine MediaThis article explores how 4DMedical (ASX:4DX) has broadened its agreement with global technology group Philips to distribute its CT-based lung-imaging platform across North America.
Insider Moves and Market Shifts at Paragon Care (ASX:PGC)
December 03, 2025 10:52 AM AEDT| By Team Kalkine MediaThis article explores the shifting dynamics at Paragon Care (ASX:PGC), focusing on insider activity, market response, and shareholder structure. It breaks down how different ownership groups influence decision-making and how the broader ASX stock mar...
Imugene (ASX:IMU) Advances CAR-T Therapy with 82% Response Rate
December 02, 2025 05:46 PM AEDT| By Team Kalkine MediaImugene Ltd (ASX:IMU) continues to demonstrate progress in immuno-oncology with azer-cel, presenting meaningful developments in lymphoma treatment and expanding its footprint in the ASX stock market.
Unlocking PME Shares: Key Insights into Pro Medicus (ASX:PME)
December 02, 2025 05:37 PM AEDT| By Team Kalkine MediaExplore the essential insights into Pro Medicus Ltd (ASX:PME) shares, highlighting financial health, software innovations, and key metrics that shape performance in the ASX stock market. Learn what makes PME a notable presence in healthcare technolog...
Imugene Advances Azer-cel as Clinical Progress Gain Momentum
December 01, 2025 08:11 PM AEDT| By Team Kalkine MediaImugene Ltd (ASX:IMU) continues to advance its immuno-oncology pipeline as its off-the-shelf CAR-T program azer-cel delivers encouraging results in people with varied forms of blood cancer. This update explores response outcomes, clinical expansion
CSL Ltd Continues to Lead Australia’s Healthcare Innovation
November 28, 2025 03:10 PM AEDT| By Team Kalkine MediaThis article explores CSL Ltd (ASX:CSL), a major name in the global biotechnology landscape, focusing on its growth drivers, business structure, and position within the ASX stock market while avoiding any investment guidance terminology.
Insider Confidence in AdAlta (ASX:1AD) Sparks ASX Buzz
November 27, 2025 07:21 PM AEDT| By Team Kalkine MediaAdAlta (ASX:1AD) has caught attention due to increased insider involvement over the past year. This long-form article explores why insider ownership matters, what recent actions may signal about the company’s direction, and how the broader
Proteomics International: Cash Use & Growth Strategy (ASX:PIQ)
November 27, 2025 06:29 PM AEDT| By Team Kalkine MediaThis article explores the cash usage and expansion strategies of Proteomics International Laboratories (ASX:PIQ), offering a clear look at how the biotechnology company navigates its funding needs while advancing research within Australia’s healthcar...
Unlocking Insights on CSL Ltd (ASX:CSL) Share Performance
November 27, 2025 05:43 PM AEDT| By Team Kalkine MediaExplore how CSL Ltd (ASX:CSL) continues to demonstrate steady growth in the ASX stock market, with a strong operational framework, revenue trends, and financial stability that make it a notable company for investors watching ASX dividend stocks.
Mesoblast (ASX:MSB) Outlook: Ryoncil Sales & Trial Update
November 27, 2025 05:38 PM AEDT| By Team Kalkine MediaExplore Mesoblast (ASX:MSB) valuation insights as Ryoncil revenue guidance and pivotal clinical trials spark market attention. Understand its market position, pipeline developments, and valuation context within the ASX stock market.
Imugene & JW Therapeutics Partner on CF33-CD19 for Tumors
November 27, 2025 04:47 PM AEDT| By Team Kalkine MediaImugene (ASX:IMU) partners with JW Therapeutics to explore CF33-CD19 in combination with CD19 Car-T therapy for solid tumors, highlighting a novel "mark and kill" approach and advancing oncology innovation on the ASX stock market.
Breakthrough Immunotherapy in Focus: Imugene (ASX:IMU) on ASX 200
November 27, 2025 04:02 PM AEDT| By SamImugene partners with JW Therapeutics to expand CAR-T therapy into solid tumours, aiming to transform oncology treatment with innovative virus-cell combination strategies impacting the ASX 200.
Recce Pharmaceuticals Expands IP Footprint in Hong Kong ASX 200 Update
November 27, 2025 03:58 PM AEDT| By SamRecce Pharmaceuticals (ASX:RCE) secures Hong Kong patent, advancing R327 and R529 anti-infectives with ongoing Phase 3 trials and expanded Asian IP footprint.
Proteomics International (ASX:PIQ) Cash Flow Overview
November 27, 2025 12:19 PM AEDT| By Team Kalkine MediaExplore how Proteomics International Laboratories (ASX:PIQ) manages its cash burn while investing in growth. Understand its cash runway, funding options, and operational resilience within the ASX stock market landscape.
Is Imricor Medical Systems (ASX:IMR) Navigating Debt Wisely?
November 27, 2025 12:06 PM AEDT| By Team Kalkine MediaThis article explores the financial health of Imricor Medical Systems (ASX:IMR), focusing on its debt management, balance sheet strength, and growth outlook. It explains how the company’s current resources position it in the ASX stock market and what...
AdAlta (ASX:1AD) Insider Activity Shows Growing Confidence in Company Outlook
November 27, 2025 11:58 AM AEDT| By Team Kalkine MediaAdAlta (ASX:1AD) insiders have shown renewed confidence through increased shareholding, reflecting their commitment to the company’s long-term growth. Insider activity highlights trust in strategic direction despite market challenges.
Advertise your brand on Kalkine Media